

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person *														5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
FALBERG KATHRYN E					Arcus Biosciences, Inc. [RCUS]								X Director		,	0% Owner		
(Last)	(First)	(Mic	dle)	3.]	3. Date of Earliest Transaction (MM/DD/YYYY)								Officer (give title below) Other (specify below)					
C/O ARCUS INC., 3928 P							3/1	9/2	018									
	(Stree			4.]	lf An	nendm	ent, Date C	Origi	nal Fil	ed (MN	M/D	D/YYYY	6. Individual	or Joint/G	roup Filing	Check Appl	icable Line)	
HAYWARD.)										X Form filed		orting Person One Reporting P	erson		
		7	Γable I -	Non-Dei	ivati	ive Sec	urities Ac	quii	red, D	ispose	d o	f, or Bo	eneficially Own	ed				
1.Title of Security (Instr. 3)			2. Tı				3. Trans. Co (Instr. 8)	or Di		Securities Acqui Disposed of (D) 1str. 3, 4 and 5)		red (A)	Following Reported Transaction(s) (Instr. 3 and 4) O			6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
							Code	V	Amou	nt (A)		Price					(Instr. 4)	
Common Stock 3/19/2018				19/2018	(С		17106 (1)	A		<u>(2)</u>		17106		I	By Trust	
Common Stock 3/19/2018				19/2018	ţ		P		30000	Α		\$15.00	80504 (4)		D			
	Tabl	e II - Deriv	ative Se	curities 1	Bene	ficially	Owned (e.g.	, puts	, calls	, w	arrants	, options, conv	ertible sec	eurities)			
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Exe	3A. Deeme Execution Date, if any		Derivat Securit (A) or I (D)				6. Date Exercisable and Expiration Date			Securities	Underlying e Security	Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	Form of Derivative Security: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exer	e rcisable	Expirati Date	ion	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)		
Series C Convertible Preferred Stock	<u>(2)</u>	3/19/2018		С			17106		<u>(2)</u>	<u>(2)</u>		Commo Stock	on 17106 (5)	(2)	0	I	By Trust	

Explanation of Responses:

- (1) The total represents shares received upon conversion of shares of Series C Convertible Preferred Stock.
- (2) The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- (3) Represents shares purchased in the Issuer's initial public offering.
- (4) The total includes 25,252 shares of Common Stock purchased by the Reporting Person on September 21, 2017 for \$2.58 per share pursuant to the exercise of an option granted on September 19, 2017 and an additional 25,252 shares of Common Stock purchased on January 25, 2018 for \$5.39 per share pursuant to the exercise of a separate option granted on January 4, 2018.
- (5) Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for \$11.6915 per share.

Reporting Owners

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
FALBERG KATHRYN E C/O ARCUS BIOSCIENCES, INC. 3928 POINT EDEN WAY HAYWARD, CA 94545	X						

Signatures

	<u></u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.